Selective antagonism of the hepatic glucocorticoid receptor reduces hepatic glucose production

Metabolism: Clinical and Experimental

Volumn 55, Issue 9, 2006, Pages 1255-1262

  Edgerton, Dale S ^a   Jacobson, Peer B ^b   Opgenorth, Terry J ^b   Zinker, Bradley ^b   Beno, David ^b   von Geldern, Tom ^b   Ohman, Lars ^c   Scott, Melanie ^a   Neal, Doss ^a   Cherrington, Alan D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ABBOTT LABORATORIES   (United States)

^c Karo Bio   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

A 348441; GLUCAGON; GLUCOCORTICOID; GLUCOCORTICOID ANTAGONIST; GLUCOCORTICOID RECEPTOR; GLUCOSE; INSULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL BLOOD; ARTICLE; CLAMP; COMPARATIVE STUDY; CONTROLLED STUDY; DIET RESTRICTION; DOG; DRUG EFFECT; DRUG SELECTIVITY; EXPERIMENTAL STUDY; FEMALE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; INSULIN BLOOD LEVEL; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD GLUCOSE; CHOLIC ACIDS; DOGS; ESTRONE; GLUCAGON; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; KINETICS; LIVER; RECEPTORS, GLUCOCORTICOID;

EID: 33747034159     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.05.011     Document Type: Article

References (42)

1. Campbell P.J., Mandarino L.J., and Gerich J.E. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Metabolism 37 (1988) 15-21
2. DeFronzo R.A., Simonson D., and Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 23 (1982) 313-319
3. Bahr V., Pfeiffer A.F., and Diederich S. The metabolic syndrome X and peripheral cortisol synthesis. Exp Clin Endocrinol Diabetes 110 (2002) 313-318
4. Andrews R.C., and Walker B.R. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 96 (1999) 513-523
5. van Schaftingen E., and Gerin I. The glucose-6-phosphatase system. Biochem J 362 (2002) 513-532
6. Hanson R.W., and Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu Rev Biochem 66 (1997) 581-611
7. Argaud D., Zhang Q., Pan W., et al. Regulation of rat liver glucose-6-phosphatase gene expression in different nutritional and hormonal states: gene structure and 5′-flanking sequence. Diabetes 45 (1996) 1563-1571
8. Darmaun D., Matthews D.E., and Bier D.M. Physiological hypercortisolemia increases proteolysis, glutamine, and alanine production. Am J Physiol 255 (1988) E366-E373
9. Nieman L.K., Chrousos G.P., Kellner C., et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 61 (1985) 536-540
10. Chu J.W., Matthias D.F., Belanoff J., et al. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 86 (2001) 3568-3573
11. Armstrong L., and Bell P.M. Addison's disease presenting as reduced insulin requirement in insulin dependent diabetes. BMJ 312 (1996) 1601-1602
12. Bamberger C.M., and Chrousos G.P. The glucocorticoid receptor and RU 486 in man. Ann NY Acad Sci 761 (1995) 296-310
13. Masuzaki H., Paterson J., Shinyama H., et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 294 (2001) 2166-2170
14. Reynolds R.M., Chapman K.E., Seckl J.R., et al. Skeletal muscle glucocorticoid receptor density and insulin resistance. JAMA 287 (2002) 2505-2506
15. Basu R., Singh R.J., Basu A., et al. Obesity and type 2 diabetes do not alter splanchnic cortisol production in humans. J Clin Endocrinol Metab 90 (2005) 3919-3926
16. Stulnig T.M., and Waldhausl W. 11beta-Hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes. Diabetologia 47 (2004) 1-11
17. Stewart P.M., Boulton A., Kumar S., et al. Cortisol metabolism in human obesity: impaired cortisone→cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 84 (1999) 1022-1027
18. Sandeep T.C., and Walker B.R. Pathophysiology of modulation of local glucocorticoid levels by 11beta-hydroxysteroid dehydrogenases. Trends Endocrinol Metab 12 (2001) 446-453
19. Opherk C., Tronche F., Kellendonk C., et al. Inactivation of the glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and ameliorates hyperglycemia in streptozotocin-induced diabetes mellitus. Mol Endocrinol 18 (2004) 1346-1353
20. Watts L.M., Manchem V.P., Leedom T.A., et al. Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54 (2005) 1846-1853
21. Liang Y., Osborne M.C., Monia B.P., et al. Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice. Metabolism 54 (2005) 848-855
22. von Geldern T.W., Tu N., Kym P.R., et al. Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes. J Med Chem 47 (2004) 4213-4230
23. Jacobson P.B., von Geldern T.W., Ohman L., et al. Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes. J Pharmacol Exp Ther 314 (2005) 191-200
24. Cherrington A.D. The role of hepatic insulin receptors in the regulation of glucose production. J Clin Invest 115 (2005) 1136-1139
25. Edgerton D.S., Cardin S., Emshwiller M., et al. Small increases in insulin inhibit hepatic glucose production solely caused by an effect on glycogen metabolism. Diabetes 50 (2001) 1872-1882
26. Lloyd B., Burrin J., Smythe P., et al. Enzymic fluorometric continuous-flow assays for blood glucose, lactate, pyruvate, alanine, glycerol, and 3-hydroxybutyrate. Clin Chem 24 (1978) 1724-1729
27. Moore M.C., Cherrington A.D., Cline G., et al. Sources of carbon for hepatic glycogen synthesis in the conscious dog. J Clin Invest 88 (1991) 578-587
28. Mari A. Estimation of the rate of appearance in the non-steady state with a two-compartment model. Am J Physiol 263 (1992) E400-E415
29. Dobbins R.L., Davis S.N., Neal D.W., et al. Pulsatility does not alter the response to a physiological increment in glucagon in the conscious dog. Am J Physiol 266 (1994) E467-E478
30. Edgerton D.S., Cardin S., Pan C., et al. Effects of insulin deficiency or excess on hepatic gluconeogenic flux during glycogenolytic inhibition in the conscious dog. Diabetes 51 (2002) 3151-3162
31. Laloux M., Stalmans W., and Hers H.G. On the mechanism by which glucocorticoids cause the activation of glycogen synthase in mouse and rat livers. Eur J Biochem 136 (1983) 175-181
32. Baque S., Roca A., Guinovart J.J., et al. Direct activating effects of dexamethasone on glycogen metabolizing enzymes in primary cultured rat hepatocytes. Eur J Biochem 236 (1996) 772-777
33. Goldstein R.E., Wasserman D.H., McGuinness O.P., et al. Effects of chronic elevation in plasma cortisol on hepatic carbohydrate metabolism. Am J Physiol 264 (1993) E119-E127
34. Goldstein R.E., Cherrington A.D., Reed G.W., et al. Effects of chronic hypercortisolemia on carbohydrate metabolism during insulin deficiency. Am J Physiol 266 (1994) E618-E627
35. Yoon J.C., Puigserver P., Chen G., et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413 (2001) 131-138
36. DeFronzo R.A., Bonadonna R.C., and Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15 (1992) 318-368
37. Pressley L., and Funder J.W. Glucocorticoid and mineralocorticoid receptors in gut mucosa. Endocrinology 97 (1975) 588-596
38. Watford M. Is the small intestine a gluconeogenic organ. Nutr Rev 63 (2005) 356-360
39. Fuller P.J., and Funder J.W. Mineralocorticoid and glucocorticoid receptors in human kidney. Kidney Int 10 (1976) 154-157
40. Gustavson S.M., Chu C.A., Nishizawa M., et al. Effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog. Metabolism 53 (2004) 933-941
41. Borgius L.J., Steffensen K.R., Gustafsson J.A., et al. Glucocorticoid signaling is perturbed by the atypical orphan receptor and corepressor SHP. J Biol Chem 277 (2002) 49761-49766
42. Yamagata K., Daitoku H., Shimamoto Y., et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 279 (2004) 23158-23165